Ryan Dunn, MD
Pulmonary Disease · Sarasota, FLNPI 1114258167
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,275 of the $30,097 with a category attached, or 67.4%. Boehringer Ingelheim accounts for 77.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $9,244 and has fallen 94.1% since, to $543 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $493.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$23K
- Intuitive Surgical$6K
- GSK$334
- AstraZeneca$324
- Genentech USA, Inc.$101
- United Therapeutics Corporation$51
- plus $71 from 2 others
Across 3 payments — averaging $3049.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$9K
What the payments were for
- Speaking & faculty fees$20,27567%
- Travel & lodging$4,40115%
- Food & beverage$1,3354%
- Education$4,08614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 25 | $23,319 |
| Intuitive Surgical | 8 | $5,897 |
| GSK | 9 | $334 |
| AstraZeneca | 11 | $324 |
| Genentech USA, Inc. | 3 | $101 |
| United Therapeutics Corporation | 2 | $51 |
| Insmed, Inc. | 2 | $51 |
| Inogen, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,853
- NUCALA$226
- TEZSPIRE$125
How this compares
$30,097 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 540 | $543,806 |
| OfevNintedanib Esylate | 12 | $160,786 |
| Breo ElliptaFluticasone/Vilanterol | 118 | $77,367 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $61,569 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $58,845 |
| Spiriva RespimatTiotropium Bromide | 17 | $23,891 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $20,052 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $10,923 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $8,379 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 259 | $5,385 |
| Mycophenolate Mofetil | 13 | $2,856 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,678 |
| Azithromycin | 167 | $2,417 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $2,152 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $1,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $334 | $682,743729 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $23,319 | $204,72955 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $324 | $69,76883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Sarasota
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.